Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers
Cancer Letters · 2025-11 · 632 · 217975
DOI: 10.1016/j.canlet.2025.217975 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Letters, 2025-11. Verfasst von Chi Ma und 17 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Colorectal Neoplasms, Gastrointestinal Microbiome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, Foundation for the National Institutes of Health, National Institutes of Health.
Abstract (Originalsprache)
A phase II study was conducted in patients with primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal (CRC) or pancreatic (PDAC) cancers to assess the effect of nivolumab (anti-PD1), oral vancomycin and tadalafil. Patients were treated with 480 mg nivolumab intravenously every 4 weeks, oral 10 mg tadalafil daily and 125 mg vancomycin orally every 6 h days 1-21 of a 28-day cycle. The primary endpoint was best overall response. Secondary endpoints included analysis of the gut microbiota, serum bile acids and immune cells in peripheral blood. A total of 22 patients were enrolled (6 HCC, 7 CRC and 9 PDAC patients). Three out of 16 evaluable patients (2 patients with HCC and 1 patient with CRC) demonstrated stable disease as best response. No unexpected adverse events were observed. A decrease in secondary bile acids along with changes in gut microbiota were observed. Vancomycin/Tadalafil/Nivolumab treatment did not cause any apparent change of major immune cell frequencies in peripheral blood however, a significant change was observed in monocyte subsets. Treatment was well tolerated and led to changes in the gut microbiome along with changes in the bile acid pool and myeloid cells in peripheral blood. No clinical activity was observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
- Cancer Data Science Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
- Center for Interventional Radiology, Radiology and Imaging Sciences, NIH Clinical Center & Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
- Laboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute, National Institutes of Health, Bethesda, Maryland NIH, Bethesda, USA.
- Molecular Pharmacology Section, Center for Cancer Research (CCR), National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- Radiology and Imaging Sciences, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Förderung
- Intramural NIH HHS
- Foundation for the National Institutes of Health
- National Institutes of Health
- U.S. Department of Health and Human Services
- National Cancer Institute
Zitieren
APA
Ma, C., Awosika, J. A., Monge, C., Coffman-D'Annibale, K., Xie, C., Skorupan, N., Hrones, D. M., Liu, M., Ma, L., Wood, B. J., Levy, E. B., Kleiner, D. E., Figg, W. D., Redd, B., McCulloch, J. A., Fernandes, M. R., Trinchieri, G., & Greten, T. F. (2025). Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers. Cancer Letters, 632, 217975. https://doi.org/10.1016/j.canlet.2025.217975
Vancouver
Ma C, Awosika JA, Monge C, Coffman-D'Annibale K, Xie C, Skorupan N, et al. Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers. Cancer Letters. 2025;632:217975. doi:10.1016/j.canlet.2025.217975
BibTeX
@article{Ma2025,
author = {Ma, Chi and Awosika, Joy A and Monge, Cecilia and Coffman-D'Annibale, Kelley and Xie, Changqing and Skorupan, Nebojsa and Hrones, Donna M and Liu, Meng and Ma, Lichun and Wood, Bradford J and Levy, Elliot B and Kleiner, David E and Figg, William D and Redd, Bernadette and McCulloch, John A and Fernandes, Miriam R and Trinchieri, Giorgio and Greten, Tim F},
title = {Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers},
journal = {Cancer Letters},
year = {2025},
volume = {632},
pages = {217975},
doi = {10.1016/j.canlet.2025.217975}
}
EUVIMED